Roth Capital Issues Optimistic Estimate for GANX Earnings
Gain Therapeutics, Inc. (NASDAQ:GANX – Free Report) – Investment analysts at Roth Capital raised their Q1 2025 earnings per share (EPS) estimates for shares of Gain Therapeutics in a research report issued on Sunday, March 30th. Roth Capital analyst B. Pachaiyappan now anticipates that the company will earn ($0.14) per share for the quarter, up […]
Gain Therapeutics, Inc. (NASDAQ:GANX – Free Report) – Investment analysts at Roth Capital raised their Q1 2025 earnings per share (EPS) estimates for shares of Gain Therapeutics in a research report issued on Sunday, March 30th. Roth Capital analyst B. Pachaiyappan now anticipates that the company will earn ($0.14) per share for the quarter, up […]
